Osmotic gradient ektacytometry - a novel diagnostic approach for neuroacanthocytosis syndromes.

INTRODUCTION

The unique red blood cell (RBC) properties that characterize the rare neuroacanthocytosis syndromes (NAS) have prompted the exploration of osmotic gradient ektacytometry (Osmoscan) as a diagnostic tool for these disorders. In this exploratory study, we assessed if Osmoscans can discriminate NAS from other neurodegenerative diseases.

METHODS

A comprehensive assessment was conducted using Osmoscan on a diverse group of patients, including healthy controls ( = 9), neuroacanthocytosis syndrome patients ( = 6, 2 VPS13A and 4 XK disease), Parkinson's disease patients ( = 6), Huntington's disease patients (n = 5), and amyotrophic lateral sclerosis patients ( = 4). Concurrently, we collected and analyzed RBC indices and patients' characteristics.

RESULTS

Statistically significant changes were observed in NAS patients compared to healthy controls and other conditions, specifically in osmolality at minimal elongation index (O), maximal elongation index (EI), the osmolality at half maximal elongation index in the hyperosmotic part of the curve (O), and the width of the curve close to the osmolality at maximal elongation index (O-width).

DISCUSSION

This study represents an initial exploration of RBC properties from NAS patients using osmotic gradient ektacytometry. While specific parameters exhibited differences, only O and O-width yielded 100% specificity for other neurodegenerative diseases. Moreover, unique correlations between Osmoscan parameters and RBC indices in NAS versus controls were identified, such as osmolality at maximal elongation index (O) vs. mean cellular hemoglobin content (MCH) and minimal elongation index (EI) vs. red blood cell distribution width (RDW). Given the limited sample size, further studies are essential to establish diagnostic guidelines based on these findings.